AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11297242
Drug: UFT (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (2 x 100 mg capsules) and leucovorin (2 x 15 mg tablets) administered after an overnight fast
Trial: 11297242
Drug: UFT (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (2 x 100 mg capsules) and leucovorin (2 x 15 mg tablets) administered 5 min after a high‐fat meal
Trial: 9259247
Drug: Oral pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pamidronate (APD)
Trial: 8512628
Drug: Milacemide 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide 1200 mg/day
Trial: 8512628
Drug: Milacemide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide (all doses combined)
Trial: 28566022
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment
Trial: 20132152
Drug: 4 mg/day
RxNorm normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/day irsogladine maleate (n = 150)
Trial: 14527077
Drug: Placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline spray for 8 weeks
Trial: 14527077
Drug: Topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nasal corticosteroids for 4 weeks followed by placebo saline spray for 4 weeks
Trial: 14527077
Drug: Placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline spray for 4 weeks followed by topical nasal corticosteroids for 4 weeks
Trial: 4056254
Drug: Theobromine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theobromine (10 mg/kg)
Trial: 7130553
Drug: Theophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5 mg/kg)
Trial: 29791287
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (anthracycline and taxane) without bevacizumab
Trial: 20429895
Drug: Yoga plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga plus Cognitive Behavioral Therapy (CBT) smoking cessation intervention
Trial: 20429895
Drug: Wellness program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wellness program plus Cognitive Behavioral Therapy (CBT) smoking cessation intervention
Trial: 10795592
Drug: 1.9 Lf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.9 Lf tetanus toxoid (0.25 ml)
Trial: 10795592
Drug: 3.75 Lf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 Lf tetanus toxoid (0.5 ml)
Trial: 6502941
Drug: L-carnitine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (900 mg, p.o. daily)
Trial: 18837470
Drug: Pol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pol + BG (5 g beta-glucan)
Trial: 16084463
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg intrarectal lidocaine jelly
Trial: 1687485
Drug: Savoxepine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savoxepine (0.5 mg)
Trial: 1687485
Drug: Chlorpromazine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (75 mg)
Trial: 1687485
Drug: Savoxepine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savoxepine (average 0.1 to 0.9 mg/d) in clinical trials
Trial: 27769289
Drug: Oily fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oily fish consumption (300 g/week)
Trial: 11165126
Drug: Mistletoe extract
RxNorm normalized name: MISTLETOE EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe extract treatment
Trial: 17980250
Drug: AZD6140 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6140 90 mg
Trial: 17980250
Drug: AZD6140 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6140 180 mg
Trial: 17980250
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg loading dose plus 75 mg once daily
Trial: 15745385
Drug: Inhaled tiotropium
RxNorm normalized name: tiotropium Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tiotropium bromide 18 microg
Trial: 15745385
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Placebo
Trial: 12479050
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg daily for four weeks
Trial: 7036285
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy (Control)
Trial: 9469330
Drug: Perioperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative treatment with one course of FAC
Trial: 18219837
Drug: Fexofenadine hydrochloride,
RxNorm normalized name: Fexofenadine Hydrochloride, 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride, 15 mg, twice daily for 8 days
Trial: 18219837
Drug: Fexofenadine hydrochloride,
RxNorm normalized name: Fexofenadine Hydrochloride, 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride, 30 mg, twice daily for 8 days
Trial: 18219837
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 8 days
Trial: 14742305
Drug: Pranlukast 300
RxNorm normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Pranlukast 300 mg twice a day
Trial: 11549425
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) 450 mg/m2 plus levamisol (B)
Trial: 21850019
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream
Trial: 9449906
Drug: 1% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% imiquimod cream
Trial: 10085475
Drug: Vehicle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle treatment
Trial: 26125735
Drug: 3D‐CRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D‐CRT + docetaxel (36 mg/m(2) once weekly for 6 weeks) + adjuvant chemotherapy
Trial: 26125735
Drug: 3D‐CRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D‐CRT + docetaxel + adjuvant chemotherapy
Trial: 20934206
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for 3 years
Trial: 20934206
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for 4 years
Trial: 19205289
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for 5 years
Trial: 12677456
Drug: Electrical Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical Stimulation Therapy (EST)
Trial: 12677456
Drug: Biofeedback Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback Therapy (BFT)
Trial: 27599667
Drug: telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan 80 mg
Trial: 12814476
Drug: FTY720 (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 (0.25 to 3.5 mg)
Trial: 6446445
Drug: Aspirin (3600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3600 mg)
Trial: 6446445
Drug: Phenylbutazone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (300 mg)
Trial: 10909992
Drug: Indomethacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (150 mg)
Trial: 27808418
Drug: Lamotrigine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (300 mg)
Trial: 27808418
Drug: Levetiracetam (3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (3,000 mg)
Trial: 15105061
Drug: NuvaRing (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuvaRing (15 microg ethinylestradiol and 120 microg etonogestrel daily)
Trial: 15105061
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (30 microg ethinylestradiol and 150 microg levonorgestrel)
Trial: 8964329
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone 500 mg Q8 hours for 10 doses followed by oral prednisone for two weeks and tapering doses thereafter
Trial: 8964329
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone one mg per kilogram of body weight for two weeks followed by tapering doses
Trial: 31785587
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OXT; 6 IU, 12 IU, 24 IU)
Trial: 28679021
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of oxytocin (10 IU)
Trial: 28679021
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of oxytocin (100 or 400 IU)
Trial: 28679021
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of oxytocin
Trial: 26355232
Drug: Aflibercept in
RxNorm normalized name: aflibercept Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept in combination with mFOLFOX6
Trial: 23002282
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with pertuzumab (arm A, n=74)
Trial: 23002282
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (arm B, n=75)
Trial: 11421877
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg b.d. plus amoxicillin 1 g b.d. and tinidazole 500 mg b.d. (RAT group)
Trial: 11421877
Drug: Maastricht triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maastricht triple therapy
Trial: 9431863
Drug: Dobutamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (1 micromol/l, 15 min) after hypoxia-reoxygenation
Trial: 8480740
Drug: Aspartame (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (15 mg/kg)
Trial: 26574828
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group).
Trial: 23430759
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of genotypes associated with an anti-inflammatory profile
Trial: 18094222
Drug: Low-dose ATRA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ATRA (1 mg/kg/day)
Trial: 10473232
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg p.o. od for 7 days
Trial: 10473232
Drug: Chloramphenicol 2-3
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloramphenicol 2-3 g p.o. od in four divided doses for 14 days
Trial: 7048518
Drug: Concurrent chemo/hormonotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemo/hormonotherapy
Trial: 24490628
Drug: VL +
RxNorm normalized name: VL-2397
DrugBank: VL-2397 (DB17796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VL + local anesthesia without analgesics
Trial: 24490628
Drug: VL +
RxNorm normalized name: VL-2397
DrugBank: VL-2397 (DB17796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VL + local anesthesia + analgesics
Trial: 21425346
Drug: Reminiscence group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence group therapy (three sessions per week for 24 weeks)
Trial: 21425346
Drug: Weekly individual
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly individual supportive interviews (control group)
Trial: 11315126
Drug: Crystalloid cardioplegia
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid cardioplegia + L-arginine
Trial: 29698966
Drug: Diamine oxidase
RxNorm normalized name: Diamine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamine oxidase (DAO) supplementation, 1 capsule b.i.d., 15 min before a meal for 30 days
Trial: 26364551
Drug: AZD2014 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2014 (50 mg twice daily)
Trial: 21306238
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg once daily)
Trial: 23097413
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma gel (PRPG)
Trial: 20942866
Drug: Concurrent arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent arm (Arm C) - R-CHOP: 6 R treatments (375 mg/m²) 2 days prior to each cycle of CHOP
Trial: 20942866
Drug: Sequential arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential arm (Arm S) - R-CHOP: 6 weekly R treatments (375 mg/m²) following six cycles of CHOP
Trial: 12744985
Drug: Preventive medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive medicine curriculum (case-based approach)
Trial: 8791949
Drug: omeprazole 500
RxNorm normalized name: amoxicillin/clarithromycin/omeprazole 500 mg-500 mg-20 mg oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 500 mg q.d.s. plus amoxycillin 20 mg b.d.
Trial: 3720571
Drug: Cholestyramine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (24 g/day)
Trial: 30558079
Drug: Bosinji granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosinji granule (2.5 g, 1.523 g of Bosinji extract)
Trial: 15295219
Drug: Palivizumab 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palivizumab 15 mg/kg
Trial: 1728190
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy (15 sessions)
Trial: 1728190
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (medication withdrawn at 16 or 24 weeks)
Trial: 1728190
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (24-week duration)
Trial: 28433518
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 10 mg/kg
Trial: 29505147
Drug: Parenteral Protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral Protein Calculator (PPC)
Trial: 24281905
Drug: n‐3 FA‐enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 FA‐enriched oral nutritional supplement (Supportan, 200 ml twice daily) providing 2.0 g EPA and 1.0 g DHA per day
Trial: 22128200
Drug: Dienogest 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 0.5 mg daily
Trial: 22128200
Drug: Dienogest 1
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest 1 mg daily
Trial: 22128200
Drug: Dienogest 2
RxNorm normalized name: dienogest 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 2 mg daily
Trial: 22128200
Drug: Dienogest 3
RxNorm normalized name: dienogest 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 3 mg daily
Trial: 7479200
Drug: Piperacillin 4
RxNorm normalized name: piperacillin 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 4 g plus tazobactam 500 mg by intravenous intermittent infusion every 8 hours
Trial: 2320708
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg q8h
Trial: 2320708
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg q12h
Trial: 2320708
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg q8h
Trial: 7367815
Drug: Anticholinergic drug
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic drug therapy
Trial: 10193254
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 10 ppm
Trial: 427822
Drug: oral L‐PAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral L‐PAM
Trial: 31490342
Drug: Daily regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily regimen of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Trial: 31490342
Drug: Participants reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants reporting stimulant use
Trial: 31490342
Drug: Participants reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants reporting other nonalcohol drug use
Trial: 1841788
Drug: bezafibrate 400
RxNorm normalized name: bezafibrate 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate 400 mg/daily
Trial: 1841788
Drug: nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 30 mg/daily
Trial: 6195483
Drug: Prizidilol 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prizidilol 200 mg once daily
Trial: 6195483
Drug: Prizidilol 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prizidilol 400 mg once daily
Trial: 25239172
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of saline water (placebo)
Trial: 22206591
Drug: Group reminiscence
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group reminiscence therapy combined with health education for 6 weeks
Trial: 11981083
Drug: Theophylline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (4 mg/kg bolus and 0.25 mg/kg/h continuous infusion for up to 96 h)
Trial: 10619543
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (8-week program including progressive muscle relaxation, guided imagery, self-instruction training, study and test-taking skills)
Trial: 7552768
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol (0.05 mg/kg)
Trial: 27904156
Drug: Benidipine plus
RxNorm normalized name: benidipine
DrugBank: Benidipine (DB09231)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine plus β-blocker
Trial: 19048338
Drug: Treated groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated groups (various treatments across groups)
Trial: 12799209
Drug: Lenercept 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenercept 0.125 mg/kg
Trial: 7699494
Drug: 1-minute increment
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-minute increment intervals of midazolam (1 mg)
Trial: 2698569
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg slow-release gallopamil (200 mg/day in two divided doses for 7 days)
Trial: 16306832
Drug: Positive selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive selective nerve root injection (SNI) results
Trial: 16306832
Drug: Negative selective
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative selective nerve root injection (SNI) results
Trial: 12088919
Drug: 0.17 mg
RxNorm normalized name: clonidine 0.17 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.17 mg GH/day (starting dose), titrated by steps of 0.17 mg GH/day every 6-8 weeks, maintenance median GH dose of 0.33 mg/day in males and 0.83 mg/day in females
Trial: 10206440
Drug: Hypoosmolality induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoosmolality induced by intravenous administration of desmopressin, liberal ingestion of water, and infusion of hypotonic (0.45%) saline solution
Trial: 2514824
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion starting at 2 mU/min up to 16 mU/min during the second stage of labour
Trial: 2514824
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion during the second stage of labour
Trial: 327432
Drug: Progressive relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive relaxation treatment
Trial: 31931444
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m2) plus cisplatin (80 mg/m2) (arm A)
Trial: 31931444
Drug: Paclitaxel (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (200 mg/m2) plus carboplatin (AUC 6) (arm B)
Trial: 31124931
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate (CD) 750 mg/d